To definitively clarify whether restoring activity of macrophages through the combined NETs and Fn14 blockade is sufficient to resolve septic AKI in vivo, we harvested F4/80+ macrophages from CLP mice receiving SIVE monotherapy or SIVE plus ITEM-2 combination therapy and adoptively transferred them to mice after CLP challenge (Figure S7A). The gene discussed is TNFRSF12A; the disease is acute kidney injury.